Healthcare Industry News: Alzheimer's
News Release - March 14, 2007
Eli Lilly and Company CEO Says Biomedical Breakthroughs Are Transforming Medicine and Promise to Radically Ease the Impact of AgingBOSTON, March 14 (HSMN NewsFeed) -- In a speech at the Chief Executives Club of Boston, Eli Lilly and Company (NYSE: LLY ) chairman and chief executive officer, Sidney Taurel, today predicted that the coming biomedical revolution will move medicine from its current state of treating symptoms to predicting and preventing diseases.
Taurel, who outlined many of the new technologies and discoveries arising from the Human Genome Project, said Massachusetts was especially important as a "laboratory for the future in health care," because of its national reputation as a hub for biotechnology and life sciences research.
New technologies and innovative life sciences are revealing a wealth of previously unknown information about disease progression and human immune response, he said. Among the new technologies are microarrays, RNA interference, bioinformatics and biomarkers. Such new information allows scientists to better predict which patients will most benefit from specific therapies. With greater understanding of how to target therapies to those most likely to benefit, pharmaceutical companies can provide better care and minimize risk.
"We believe we're in the early stages of a major leap forward in new drug discovery. With all the new ideas and new tools emerging from the biomedical revolution, we see the potential to develop and deliver highly customized treatments, optimized for specific patient populations," Taurel said.
"This is the concept behind a tailored therapeutics model. The ultimate vision would be to predictably deliver to the patient 'the right dose of the right drug at the right time.'"
Tailoring has the potential to eliminate waste and make every dollar deliver benefit, he noted.
Taurel said the technological revolution in the development of new drugs and therapies -- which he described in some detail -- promises better, more- effective treatments for a whole range of diseases. "I believe that treatments that would have been regarded as miraculous ten years ago will be in common use in the future," he said.
He outlined some of the areas where huge advances could soon be made, saying the scientific community "may be right on the edge of a breakthrough in Alzheimer's." He said there is hope that pharmaceutical therapies could soon make cancer a chronic disease rather than a fatal one, repair cardiovascular damage and reverse heart disease. Taurel predicted a much better quality of life for the aging Americans.
"When you add up the progress already made in the illnesses that cause much of the disability for seniors and project it forward, you can see major improvement on so many fronts. In addition, our scientists foresee new treatments to preserve cognition and mobility and to fight frailty and pain. Old age will take on a new meaning," he said.
Taurel concluded by stating his optimism for the future of health care. "All of this is possible -- in terms of science and technology -- but none of it is guaranteed. I'm hopeful our public policies will support the continued innovations that will help us realize this incredible potential."
To see the full text of Taurel's speech, please go to www.lilly.com.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
Source: Eli Lilly
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsLilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health
Lilly Announces Leadership Changes in Corporate Business Development, Oncology R&D, and Managed Healthcare Services
Lilly Announces Positive Results for Emgality(R) (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments